Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024
June 1, 2024
Shasqi presents results from a Phase 2a study of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced STS patients at the 2024 Annual Clinical Society of Oncology (ASCO) meeting in Chicago.
